Niagen Bioscience CEO Robert Fried discusses the science of NAD, the problems with the supplement industry, and how his company is leading the way in anti-aging research.

Executives from Niagen Bioscience, Pushly, and VidaCorp discuss brand evolution. Learn why authenticity, community, and AI are key to building a resilient brand.

This initiative is part of the brand’s commitment to providing guests with science-backed health and wellness services.

Niagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical ...

Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine ...

Niagen Bioscience Inc. (NASDAQ:NAGE) saw its stock rise 2% after securing an exclusive global commercial license from Norway’s Haukeland University Hospital to develop its nicotinamide riboside ...

Niagen Bioscience (NASDAQ:NAGE) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement ...

By participating in BIO 2025, Niagen Bioscience is seeking to initiate discussions with prospective partners to support the development and monetization of its emerging drug product candidates.

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide Outperforming NAD+ IV, Niagen IV (patented nicotinamide riboside or NR) provides ...

Niagen Bioscience, Inc., the global authority on NAD+ with a focus on the science of healthy aging, today announced the continued expansion of its clinical footprint with additional new clinics ...